An AmpC-type ␤-lactamase conferring high-level resistance to expanded-spectrum cephalosporins and monobactams was characterized from an Acinetobacter baumannii clinical isolate. This class C ␤-lactamase (named ADC-33) possessed a Pro210Arg substitution together with a duplication of an Ala residue at position 215 (inside the ⍀-loop) compared to a reference AmpC cephalosporinase from A. baumannii. ADC-33 hydrolyzed ceftazidime, cefepime, and aztreonam at high levels, which allows the classification of this enzyme as an extended-spectrum AmpC (ESAC). Site-directed mutagenesis confirmed the role of both substitutions in its ESAC property.
The A. baumannii KI clinical isolate was obtained from a rectal screening of a patient who had been transferred from the Guadeloupe Islands (French Caribbean islands) and admitted at the Raymond Poincaré Hospital (Garches, Paris, France) in January 2009. This patient did not receive any antibiotic treatment. A. baumannii KI was selected for further study on the basis of its uncommon pattern of resistance to ␤-lactam antibiotics, including high-level resistance to expanded-spectrum cephalosporins and reduced susceptibility to carbapenems. In addition, it was resistant to cotrimoxazole and fluoroquinolones and susceptible to aminoglycosides.
Susceptibility testing was performed by use of the Etest (17) and interpreted according to the CLSI guidelines (5) . It showed that A. baumannii KI was resistant to amino-, carboxy-, and ureidopenicillins, to expanded-spectrum cephalosporins, including ceftazidime, cefotaxime, ceftriaxone, cefepime, and cefpirome, and to aztreonam and had reduced susceptibilities to imipenem and meropenem (see Table 2 ). By use of cloxacillin-containing plates as described previously (22) , the susceptibilities to ceftazidime and cefepime were restored, suggesting (i) overproduction of the AmpC ␤-lactamase and (ii) the likelihood for this AmpC to possess ESAC properties. Mating-out assays and electrotransformation were performed as described previously (20) but failed to transfer any cephalosporin resistance marker from A. baumannii KI to A. baumannii BM4547 or to Escherichia coli TOP10 recipient strains, suggesting that this resistance to expanded-spectrum cephalosporins was chromosomally conferred. Whole-cell DNA of A. baumannii KI was extracted as described previously (22) . Primers PreAmpC-PISAba1 and PreAmpC-Ab1 were used in combination with primer PreAmpC-Ab2 to amplify 1,521-bp and 1,254-bp fragments, respectively, encompassing the entire bla AmpC gene with and without the P ISAba1 promoter, respectively (Table 1 ). All the inserts containing the P ISAba1 promoter are named with "Pϩ" accordingly. The amplification products were cloned into E. coli TOP10 by using the ZeroBlunt-TOPOPCR cloning kit (Invitrogen, Cergy-Pontoise, France) followed by selection on plates containing 50 g/ml of amoxicillin and 30 g/ml of kanamycin. A. baumannii strain AYE and the CIP7010 reference strain were used to clone two reg-ular bla AmpC ␤-lactamase genes (7, 18) . Strain AYE corresponds to a multidrug-resistant isolate from France (19) whose complete genome sequence was determined (6, 24) . DNA sequence analysis showed that the ␤-lactamase from strain KI, named ADC-33, had 8 and 7 amino acid changes compared to regular ␤-lactamases ADC-50 and ADC-11, corresponding to the ADC ␤-lactamases of strains CIP7010 and AYE, respectively (Fig. 1) . No amino acid change was identified among the conserved SVSK, YSN, and KTG motifs, neither in helix H-2 nor in helix H-10, previously associated with the extendedspectrum activity of ESACs (12, 14, 22) . However, we identified a single amino acid substitution, Pro210Arg, associated with a duplication of the Ala residue at position 215, both of them located inside the ⍀-loop. Thus, the molecular basis of the extended-spectrum hydrolysis profile of ADC-33 might be related to those specific substitutions. The presence of the insertion sequence ISAba1 providing strong promoter sequences (Ϫ35 [TTAGAA] and Ϫ10 [TTATTT]) immediately upstream of the bla AmpC gene was noticed, as previously observed when the bla AmpC gene was overexpressed (9) .
MICs of all ␤-lactams for the different clones were higher in the presence of the P ISAba1 promoter ( Table 2 ). E. coli TOP10(pADC-33-Pϩ) was resistant to most ␤-lactams except cefepime, cefpirome, and carbapenems. E. coli TOP10(pADC-11-Pϩ), producing a regular cephalosporinase, was resistant to amoxicillin and to narrow-spectrum cephalosporins and remained susceptible to the expanded-spectrum cephalosporins, including ceftazidime, cefotaxime, cefepime, and cefpirome, and aztreonam ( Table 2 ). The recombinant E. coli strain harboring the bla ADC-33 gene showed a broadened hydrolytic activity against ceftazidime, cefotaxime, cefepime, cefpirome, and aztreonam compared to that of the regular variant, increasing the resistance rates significantly (from 8-to 128-fold), suggesting that ADC-33 might be considered an ESAC enzyme. In order to better define the clinical impact of this ADC-33 variant, recombinant plasmids pADC-33-Pϩ and pADC-11-Pϩ were additionally electrotransformed into E. coli HB4 (lacking OmpC and OmpF porins) (13) . By using E. coli HB4, our aim was to mirror the intrinsic weak permeability of A. baumannii and therefore better appreciate the impact of the ESAC enzymes. MICs of cefepime, cefpirome, and aztreonam for the ESAC and regular variants were 32, 128, and Ͼ256 g/ml and 2, 4, and 12 g/ml, respectively (data not shown). Those MIC values were higher than those observed for the 
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A. baumannii Isoelectric focusing analysis performed as described previously (21) using crude culture extracts of A. baumannii KI and of the different clones obtained by sonication gave a single ␤-lactamase signal for all of them, corresponding to a pI value of 9.3, consistent with the production of an AmpC ␤-lactamase.
␤-Lactamases ADC-33 and ADC-11 were purified to near homogeneity (Ͼ99%) as previously described (20) . The molecular mass of those proteins determined by SDS-PAGE analysis was 43 kDa. The specific activities, determined with 100 M benzylpenicillin as the substrate, were 45 and 55 mol/ min/mg of protein for ADC-33 and ADC-11, respectively.
Purified ␤-lactamases ADC-33 and ADC-11 were used for kinetic measurements (K m and k cat ) calculated as described previously (20) . The kinetic parameters for penicillins and carbapenems for the two AmpC enzymes were similar, whereas the catalytic efficiency of the purified ␤-lactamase ADC-33 against cephalosporins was higher than that of ADC-11 (Table  3) . This higher catalytic efficiency observed for ADC-33 was noticeable in particular for ceftazidime, cefotaxime, cefepime, cefpirome, and aztreonam (Table 3) . Those data confirmed the ESAC property of ADC-33, which associates two specific features, namely, (i) a greater ability to hydrolyze ceftazidime, cefotaxime, and aztreonam than a regular AmpC and (ii) an extended-spectrum activity toward cefepime and cefpirome, which are substrates usually weakly hydrolyzed by regular AmpCs.
No significant difference in 50% inhibitory concentrations (IC 50 s) for clavulanic acid was observed between the two enzymes (1.6 and 2.1 mM, for ADC-33 and ADC-11, respectively).
Compared to the regular ADC-11 ␤-lactamase, ADC-33 contained several amino acid substitutions, including the substitution Pro210Arg together with a duplication of the Ala residue at position 215 located inside the ⍀-loop. A site-directed mutagenesis strategy was used with a protocol described by the manufacturer (QuikChange site-directed mutagenesis kit; Stratagene) and as reported previously (21) for evaluation of the amino acid changes that could be involved in the extended-spectrum resistance spectrum of ADC-33. By use of recombinant plasmids pADC-33-Pϩ and pADC-11-Pϩ as templates and primers KI-A215-DelF/KI-A215-DelR and Aye-A215-InsF/Aye-A215-InsR, deletion and insertion of the Ala215 residue, respectively, were performed (Table 1) . This allowed us to obtain recombinant plasmids pADC-33-Pϩ(A215Del) (with a single A215 residue) and pADC-11-Pϩ(A215Ins) (with two A215 residues). Then, the Arg210Pro and Pro210Arg mutants were generated by using primer pairs KI-R210P-F/KI-R210P-R and Aye-P210R-F/Aye-P210R-R, respectively (Table 1) , with other recombinant strains obtained in a second step as indicated in Table 2 . Sequence analysis of the different inserts confirmed the presence of the expected amino acid changes.
Duplication of the Ala215 residue in ␤-lactamase ADC-11 resulted in a pattern of increased resistance toward expandedspectrum cephalosporins (Table 2) which was, however, not sufficient to explain MIC differences observed between E. coli (pADC-11-Pϩ) and E. coli . Thus, as a second step, the Pro210Arg substitution was performed, allowing us to achieve an ESAC phenotype identical to that of ADC-33. Conversely, the Arg210Pro substitution performed with ADC-33 allowed the recovery of the regular AmpC phenotype, supporting the hypothesis that both amino acid modifications (Ala215 duplication and Pro210Arg substitution) were responsible for the extended-spectrum profile of ADC-33 (Table 2) . Whether the other identified amino acid differences between ADC-33 and ADC-11 ( Fig. 1) could play a specific role in the functionality or stability of ␤-lactamase ADC-33 remains unclear.
Extension of the ⍀-loop for AmpC ␤-lactamase from Enterobacter cloacae has been shown to broaden its hydrolysis spectrum (15, 16) . In that case, the mutant enzyme exhibited an increased opening of the entrance of the substrate-binding pocket (6) . The Ala215 duplication observed here in AmpC ADC-33 might have similar consequences for its hydrolysis spectrum.
We describe here the first ESAC conferring resistance to 
